$HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China$

PremiumPress Releases

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

15h ago

HCM

PremiumPress Releases

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

15h ago

HCM

PremiumCompany Announcements

HUTCHMED AGM Concludes with Solid Shareholder Approval

4d ago

PremiumCompany Announcements

HUTCHMED Appoints New Board Director

6d ago

PremiumPress Releases

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

6d ago

HCM

More GB:HCM News >

HCM News on the Web

2024-05-14

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

Yahoo Finance UK

Neutral

2024-05-14

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

Yahoo Finance UK

Neutral

2024-05-14

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

Yahoo Finance

Neutral

2024-05-08

HUTCHMED Appoints New Board Director

TipRanks News

Neutral

2024-05-08

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Yahoo Finance UK

Neutral

2024-04-26

HUTCHMED’s Fruquintinib Close to EU Approval

TipRanks News

Neutral

2024-04-26

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

Yahoo Finance UK

Neutral

2024-04-24

HUTCHMED shareholders are up 8.2% this past week, but still in the red over the last five years

Yahoo Finance

Neutral

News Score - Last 7 Days

Neutral

GB:HCM

Sector Average

Media Buzz

This Week5 articles

Weekly Average2.25 articles

News Sentiment

This Week50%

Sector Average61%

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is GB:HCM’s Media Buzz Sentiment?

5 articles about GB:HCM were published this week. In an average week, 2.25 articles are published.

What is GB:HCM’s weekly average amount of articles?

In an average week, 2.25 articles about GB:HCM are published.

What is GB:HCM’s News Sentiment?

50% of articles about GB:HCM were positive this week, compared to its sector average of 61%.

Healthcare Stocks that are Trending in the News

CYTKCytokinetics

MTDMettler-Toledo

PHVSPharvaris

IMCRImmunocore Holdings

HAEHaemonetics

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing